Sinusitis, Acute
Conditions
Keywords
Acute bacterial rhinosinusitis, Amoxicilin, Infection, Potassium clavulanate
Brief summary
Acute Bacterial Rhinosinusitis (ABRS) is a respiratory inflammation commonly seen in clinical practice, which has with respiratory symptoms including nasal congestion, rhinorrhoea, postnasal discharge and cough and is associated with headache, cheek pain, facial pressure and other conditions. The principal bacterial pathogens in causing ABRS include Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis. These three bacteria account for approximately 90% of ABRS in children less than or equal to 5 years of age. Combination of Potassium Clavulanate (CVA) and Amoxicillin (AMPC) produces higher antibiotic activity against beta-lactamase-producing bacteria. The present study is designed to assess the clinical efficacy, bacteriological efficacy and safety of CVA/AMPC (1:14) administered in children aged from 3 months to less than 15 years with ABRS. It is an open-label study consisting of a 7-day treatment phase and a post-treatment follow-up phase for 7 to 14 days.
Interventions
The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Months to 15 Years
Healthy volunteers
No
Inclusion criteria
* Child with ABRS with inflammation as bacterial infection who has the following symptoms/signs on the day of or the day before the first dose of the investigational product: Redness of the nasal mucosa; nasal or postnasal discharge is purulent or mucopurulent; Pathological shadow in the paranasal sinus on a radiogram (only for reference). Patient with surgical history should be excluded but patient with a pervious surgery more than 365 days before and apparently preserved maxillary sinus mucosa or patient with a previous surgery of nasal polypectomy more than 90 days before may be enrolled in the study. * Child with ABRS whose severity is classified as moderate or severe (total score \>=4) based on the nasal cavity findings and symptoms. * Boy or girl aged \>=3 months to \<15 years. * Body weight \>=6 kilograms (kg) to \<40 kg. * Written informed consent has been obtained from the child's legally acceptable representative. If the child is 12 years or older, the child him/herself should have also provided written informed consent. The investigator (or sub-investigator) should attempt to obtain written informed consent from the child him/herself as far as possible even if the child is less than 12 years of age.
Exclusion criteria
* Severe infection that requires surgical treatment (e.g., child with systemic symptoms such as fever associated with swelling face, child with almost full nasal obstruction due to a large nasal polyp). * Serious complication such as acute mastoiditis, facial palsy, bacterial meningitis, and brain tumor. * Congenital disorder such as maxillofacial dysplasia. * Need of concomitant use of other antibiotics. * Serious underlying disease (e.g., cardiac disease, malignancy, juvenile diabetes). * Concurrent infection associated with gastrointestinal symptoms (e.g., diarrhoea, vomiting) that may affect safety assessment. * Known hypersensitivity to any component of CVA/AMPC or penicillin or cephem antibiotic, or past history of a serious adverse reaction possibly related to any of these agents. * Infectious mononucleosis. * Current hepatic impairment, or past history of jaundice or hepatic impairment due to any component of CVA/AMPC. * Past or current renal impairment (e.g., serum creatinine \>=1.5 × Upper Limit of Normal, creatinine clearance of less than 30 milliliter/liter \[mL/L\]). * Past or current immune dysfunction or insufficiency, or use of immunosuppressive therapy. * Need corticosteroid for systemic, eye drops or nasal drops. * Phenylketonuria. * Use of azithromycin within 14 days prior to the first dose of the investigational product. * Use of any antibiotic within 7 days prior to the first dose of the investigational product. * Current use or imperative use during the study period of probenecid or a tubular secretion inhibitor. * Participation in another clinical study within 3 months prior to enrollment, or prospected participation in another clinical study during the period of this study. * Girl with menstruation and childbearing potential, pregnant girl, lactating girl, or girl who is planning a pregnancy during the study period. A girl with childbearing potential may be enrolled in the study only if she is willing to use at least one of the following acceptable measures for contraception throughout the study period: Male partner sterilization prior to the girl's entry into the study, and this male is the sole partner for that girl; Intrauterine device (IUD) (with documented annual failure rate estimate of \<1%); Abstinence; Male condom combined with a female diaphragm, either with or without a vaginal spermicide. * The legally acceptable representative is a minor. * Child in care. * History of alcohol or drug abuse. * Relationship with the study medical institution: The investigator, sub-investigator, study collaborator, person employed by the investigator or the study medical institution, or their close relatives. * Child whose participation in the study is considered inappropriate by the investigator (or sub-investigator).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC: Day 15) | Day 15 | Clinical assessment of acute bacterial rhinosinusitis was performed by the investigator (or subinvestigator) at TOC (Day 15) on the basis of the following criteria: Cure is defined as sufficient resolution or improvement of the signs and symptoms such that no additional antibiotic therapy is needed. Failure is defined as no change or deterioration of the signs and symptoms or as additional antibiotic therapy being needed. The outcome was unable to be determined if no information was available regarding the signs and symptoms or, despite improvement of the signs and symptoms, the use of a non-study antibiotic was administered, indicating that there was a protocol deviation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT: Day 8) | Day 8 | Clinical assessment of acute bacterial rhinosinusitis was performed by the investigator (or subinvestigator) at the EOT (Day 8) on the basis of the following criteria: Cure is defined as sufficient resolution or improvement of the signs and symptoms such that no additional antibiotic therapy is needed. Failure is defined as no change or deterioration of the signs and symptoms or as additional antibiotic therapy being needed. The outcome was unable to be determined if no information was available regarding the signs and symptoms or, despite improvement of the signs and symptoms, the use of a non-study antibiotic was administered, indicating that there was a protocol deviation. |
| Number of Participants With a Clinical Outcome of Cure at Both the End of Treatment and Test of Cure (EOT and TOC: Day 8 and Day 15) | Day 8 and Day 15 | Clinical assessment of acute bacterial rhinosinusitis was performed by the investigator (or subinvestigator) at the EOT (Day 8) and TOC (Day 15) on the basis of the following criteria: Cure is defined as sufficient resolution or improvement of the signs and symptoms such that no additional antibiotic therapy is needed. Failure is defined as no change or deterioration of the signs and symptoms or as additional antibiotic therapy being needed. The outcome was unable to be determined if no information was available regarding the signs and symptoms or, despite improvement of the signs and symptoms, the use of a non-study antibiotic was administered, indicating that there was a protocol deviation. In order to be categorized as cure, participants had to meet the criteria for cure at both Day 8 and Day 15. |
| Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Baseline (BL), Day 4, Day 8, and Day 15 | The investigator (or sub-investigator) categorized the severity of symptoms such as rhinorrhoea and bad mood/productive cough as none, mild/small amount (M/SA), or moderate or severe (M or S). For the nasal cavity finding of nasal/postnasal discharge (N/PD) the categozation was serous \[containing serum\]), mucopurulent (MU/SA \[containing both mucus and pus\]), and moderate or larger amount (M/LA). In cases in which both sides of the nasal cavity were affected and there was no difference in severity between the sides, the right-side results were recorded. If there was a difference in severity, the more severe-side results were recorded. |
| Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Day 8 | The investigator used the sample collected at the start of study treatment (trt) to isolate and identify the pathogenic bacteria. The sample collected at the EOT was used to evaluate the bact. response to the investigational product of each path. If the same pathogen was not detected at the EOT, this pathogen was classified as eradication (E). If the same pathogen was detected at the EOT, this pathogen was classified as persistence (P). |
| Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Participant at EOT (Day 8) | Day 8 | The investigator used the sample collected at the start of study treatment (trt) to isolate and identify the pathogenic bacteria. The sample collected at the EOT was used to evaluate the bact. response to the investigational product of each par. using the following classification: Bact. eradication (erad.), presumed bact. erad. and colonization were categorized as erad. Bact. persistence (pers.), presumed bact. pers. and superinfection were categorized as pers. Bact. erad. elimination of the pathogen (path.) after trt; presumed bact. erad.-resolution of signs/symptoms (s/s) after trt; colonization-resolution of s/s but initial path. still recovered from sample; bact. pers.-no improvement in s/s and initial path. was recovered from sample; presumed bact. pers.-no improvement in s/s and isolation of initial path. was impossible/not performed; superinfection-initial path. was eradicated but a new path. was recovered; unable to determine-bact. test could not be performed. |
Countries
Japan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| CVA/AMPC (1:14) Participants received an oral dose of dry syrup potassium clavulanate (CVA)/amoxicillin hydrate (APMC) for 7 days. The daily dose of CVA/AMPC (1:14) was equal to CVA 6.4 milligrams (mg) (potency)/kilogram (kg)/day and AMPC 90 mg (potency)/kg/day in two divided doses (every 12 hours) just before lactation or meal depending on body weight at the start of treatment (Day 1). | 27 |
| Total | 27 |
Baseline characteristics
| Characteristic | CVA/AMPC (1:14) |
|---|---|
| Age, Continuous | 6.6 Years STANDARD_DEVIATION 2.42 |
| Race/Ethnicity, Customized Asian - Japanese Heritage | 27 Participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 5 / 27 |
| serious Total, serious adverse events | 0 / 27 |
Outcome results
Primary
Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC: Day 15)
Clinical assessment of acute bacterial rhinosinusitis was performed by the investigator (or subinvestigator) at TOC (Day 15) on the basis of the following criteria: Cure is defined as sufficient resolution or improvement of the signs and symptoms such that no additional antibiotic therapy is needed. Failure is defined as no change or deterioration of the signs and symptoms or as additional antibiotic therapy being needed. The outcome was unable to be determined if no information was available regarding the signs and symptoms or, despite improvement of the signs and symptoms, the use of a non-study antibiotic was administered, indicating that there was a protocol deviation.
Time frame: Day 15
Population: Per Protocol (PP) Population: all participants randomized to treatment who received the study drug for at least the first 3 days of study treatment in the Treatment Period and had evaluable data on both Day 8 and Day 15 with treatment compliance between 80% and 100% and no major protocol deviations
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC: Day 15) | Failure | 3 Participants |
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC: Day 15) | Cure | 23 Participants |
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC: Day 15) | Unable to Determine | 0 Participants |
95% CI: [69.85, 97.55]
Secondary
Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Participant at EOT (Day 8)
The investigator used the sample collected at the start of study treatment (trt) to isolate and identify the pathogenic bacteria. The sample collected at the EOT was used to evaluate the bact. response to the investigational product of each par. using the following classification: Bact. eradication (erad.), presumed bact. erad. and colonization were categorized as erad. Bact. persistence (pers.), presumed bact. pers. and superinfection were categorized as pers. Bact. erad. elimination of the pathogen (path.) after trt; presumed bact. erad.-resolution of signs/symptoms (s/s) after trt; colonization-resolution of s/s but initial path. still recovered from sample; bact. pers.-no improvement in s/s and initial path. was recovered from sample; presumed bact. pers.-no improvement in s/s and isolation of initial path. was impossible/not performed; superinfection-initial path. was eradicated but a new path. was recovered; unable to determine-bact. test could not be performed.
Time frame: Day 8
Population: Bacteriology PP Population: all participants in the PP Population, excluding the participants who were classified as Unable to determine for the bacteriological outcome and who had no identified pathogen at Day 1
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Participant at EOT (Day 8) | Eradication | 24 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Participant at EOT (Day 8) | Persistence | 0 Participants |
Secondary
Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8
The investigator used the sample collected at the start of study treatment (trt) to isolate and identify the pathogenic bacteria. The sample collected at the EOT was used to evaluate the bact. response to the investigational product of each path. If the same pathogen was not detected at the EOT, this pathogen was classified as eradication (E). If the same pathogen was detected at the EOT, this pathogen was classified as persistence (P).
Time frame: Day 8
Population: Bacteriology PP Population: all participants in the PP Population, excluding the participants who were classified as Unable to determine for the bacteriological outcome and who had no identified pathogen at Day 1
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Streptococcus pyogenes, E | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Enterobacter species (sp), E | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Coagulase (Coag) NStaph, E | 3 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Corynebacterium sp., E | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Corynebacterium sp., P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Pseudomonas aeruginosa, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Streptococcus pneumoniae (StPn), E | 8 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | StPn, P | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Penicillin Susceptible (PenSusc) StPn, E | 7 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | PenSuscStPn, P | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Pen Intermediate (PenInt) StPn, E | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | PenIntStPn, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Pen Resistant (PenR) StPn, E | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | PenRStPn, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Moraxella (Branhamella) catarrhalis (MBC), E | 6 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | MBC, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | MBC beta-lactamase (BL) positive, E | 6 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | MBC BL positive, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | MBC BL negative (N), E | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | MBC BLN, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Haemophilus influenzae (HI), E | 8 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | HI, P | 6 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | HI BLN ampicillin (A) susceptible (S), E | 8 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | HI BLNAS, P | 2 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | HI BLNA resistant (R), E | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | HI BLNAR, P | 3 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | HI BL Producing (Pr) AR, E | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | HI BLPrAR, P | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Staphylococcus aureus (Staph Ar), E | 5 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Staph Ar, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Methicillin R Staph Ar, E | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Methicillin R Staph Ar, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Streptococcus pyogenes, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Enterobacter sp., P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | CoagNStaph, P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Streptococcus sp., E | 1 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Streptococcus sp., P | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants (Par.) With the Specified Bacteriological (Bact.) Outcome Per Pathogen (Path.) at the End of Treatment (EOT) at Day 8 | Pseudomonas aeruginosa, E | 0 Participants |
Secondary
Number of Participants With a Clinical Outcome of Cure at Both the End of Treatment and Test of Cure (EOT and TOC: Day 8 and Day 15)
Clinical assessment of acute bacterial rhinosinusitis was performed by the investigator (or subinvestigator) at the EOT (Day 8) and TOC (Day 15) on the basis of the following criteria: Cure is defined as sufficient resolution or improvement of the signs and symptoms such that no additional antibiotic therapy is needed. Failure is defined as no change or deterioration of the signs and symptoms or as additional antibiotic therapy being needed. The outcome was unable to be determined if no information was available regarding the signs and symptoms or, despite improvement of the signs and symptoms, the use of a non-study antibiotic was administered, indicating that there was a protocol deviation. In order to be categorized as cure, participants had to meet the criteria for cure at both Day 8 and Day 15.
Time frame: Day 8 and Day 15
Population: PP Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at Both the End of Treatment and Test of Cure (EOT and TOC: Day 8 and Day 15) | Cure | 23 Participants |
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at Both the End of Treatment and Test of Cure (EOT and TOC: Day 8 and Day 15) | Failure | 3 Participants |
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at Both the End of Treatment and Test of Cure (EOT and TOC: Day 8 and Day 15) | Unable to Determine | 0 Participants |
Secondary
Number of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT: Day 8)
Clinical assessment of acute bacterial rhinosinusitis was performed by the investigator (or subinvestigator) at the EOT (Day 8) on the basis of the following criteria: Cure is defined as sufficient resolution or improvement of the signs and symptoms such that no additional antibiotic therapy is needed. Failure is defined as no change or deterioration of the signs and symptoms or as additional antibiotic therapy being needed. The outcome was unable to be determined if no information was available regarding the signs and symptoms or, despite improvement of the signs and symptoms, the use of a non-study antibiotic was administered, indicating that there was a protocol deviation.
Time frame: Day 8
Population: PP Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT: Day 8) | Unable to Determine | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT: Day 8) | Cure | 25 Participants |
| CVA/AMPC (1:14) | Number of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT: Day 8) | Failure | 1 Participants |
Secondary
Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15
The investigator (or sub-investigator) categorized the severity of symptoms such as rhinorrhoea and bad mood/productive cough as none, mild/small amount (M/SA), or moderate or severe (M or S). For the nasal cavity finding of nasal/postnasal discharge (N/PD) the categozation was serous \[containing serum\]), mucopurulent (MU/SA \[containing both mucus and pus\]), and moderate or larger amount (M/LA). In cases in which both sides of the nasal cavity were affected and there was no difference in severity between the sides, the right-side results were recorded. If there was a difference in severity, the more severe-side results were recorded.
Time frame: Baseline (BL), Day 4, Day 8, and Day 15
Population: PP Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 4, None | 7 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 8, M/SA | 13 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 8, M or S | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 4, M/SA | 10 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: BL, None | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: BL, M/SA | 5 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 4, Serous | 14 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 4, MU/SA | 10 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: BL, M or S | 21 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 4, M/LA | 2 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 4, M/SA | 16 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 4, M or S | 3 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 8, None | 13 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 8, Serous | 22 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 8, MU/SA | 4 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 8, M/LA | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 15, Serous | 21 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 15, MU/SA | 5 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: Day 15, M/LA | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 15, None | 18 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 15, M/SA | 8 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Rhinorrhoea: Day 15, M or S | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: BL None | 4 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: BL, M/SA | 20 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: BL, M or S | 2 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 4, None | 16 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 4, M or S | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 8, None | 21 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 8, M/SA | 5 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 8, M or S | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 15, None | 24 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 15, M/SA | 2 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | Bad mood/productive cough: Day 15, M or S | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: BL, Serous | 0 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: BL, MU/SA | 6 Participants |
| CVA/AMPC (1:14) | Number of Participants With the Indicated Severity of Symptoms and Nasal Cavity Findings at Day 4, Day 8, and Day 15 | N/PD: BL, M/LA | 20 Participants |